caused by emboli of fibrin-platelet aggregates derived from atheromatous lesions of the carotid artery or from the cardiac valves. In our previous study of amaurosis fugax 10% of patients were under the age of 40 when they presented.2 Advanced atherosclerotic carotid artery disease is unlikely to be present in this age group and no significant cardiac lesions were detected. Eadie, et al reported 12 patients between the ages of 14 and 51 years with amaurosis fugax of whom eight had carotid arteriograms all of which were normal; none had cardiological investigations and they suggested that uniocular visual loss was benign in this age group. 3 Amaurosis fugax has been reported in patients with secondary thrombocytosis and essential thrombocythaemia.4 Treatment with aspirin 325mg tid and persantin 100mg tid returned the haematological abnormalities to normal and abolished the amaurosis fugax in the few patients described.
Increased platelet aggregation with normal total platelet counts has been found in patients during the interval and prodromal phases of migraine,56 in oph-thalmoplegic migraine,7 cerebral transient ischaemic attacks and after cerebral infarcts.8 9 We report here some aspects of platelet function in a group of young patients with amaurosis fugax to determine whether a primary platelet disorder was contributing to or responsible for their symptoms. focal leakage of fluorescein. Three years later she still has a residual sectorial field defect and continues to experience amaurosis fugax in the same eye. All patients had a normal full blood count, peripheral platelet count, ESR, and serum VDRL and TPHA. Carotid arteriography (including four digital subtraction angiograms after iv injection) was normal in the 10 patients who underwent this investigation. Fourteen patients had echocardiography which was normal in all cases. No patient had cardiac disease, hypertension, diabetes, evidence of arteritis or polycythaemia. Five smoked cigarettes and two had cold sensitivity of the Raynaud type.
The results of spontaneous platelet aggregation, platelet aggregation with AA and ADP and platelet release protein concentrations are shown in table 2.
One patient (AC) was studied 2 hours after an attack when spontaneous platelet aggregation and platelet hyperaggregability to low concentrations of AA and ADP could be demonstrated. When these tests were repeated one week after her previous attack, spontaneous platelet aggregation was still present but there was no evidence of hyperaggregability to AA or ADP. Treatment with aspirin 75 mg daily abolished spontaneous platelet aggregation but did not stop her amaurosis fugax. Three other patients includingthe daughter of AC had hyperaggregable platelets to AA and ADP between attacks of amaurosis fugax and in one case spontaneous aggregation was observed. In one other patient (AM) platelet aggregation was studied 12 hours after an attack but no significant abnormality in platelet aggregation to AA or ADP was found. MH, BM, AM, SB and RS also were treated with 75 or 300mg aspirin daily but this had no effect-on,the frequency or duration-of their attacks. Platelet release protein assays were all normal apart from in one patient (MH) who subsequently was found to have carcinoma of the cervix.
Discussion
As previously noted there is a group of young patients with amaurosis fugax who have a favourable prognosis.-None of the patients in this group developed symptoms of cerebral or cardiac ischaemia. One patient suffered a permanent sectorial field defect but apart from her attacks sometimes being associated with headache, there were no distinguishing features about her amaurosis fugax. She and one otherpatient in this group also had attacks of migraine but this may occur in a similar proportion of the general population.
In this series all carotid arteriograms were normal suggesting that this investigation is probably unnecessary in this age group. Similarly, all echocardiograms were normal in these patients although Wilson et al have reported an association between amaurosis fugax and mitral leaflet prolapse.'0 A relatively high proportion of the patienits studied, four out of ten, demonstrated evidence of platelet hyperaggregability compared with normal controls. Two of these had had attacks of uniocular visual loss associated with headache and one later developed carcinoma of the cervix. One patient with platelet hyperaggregability continued to experience amaurosis fugax despite correction of platelet hyperaggregability with aspirin. In five other patients who took aspirin regularly, including two with platelet hyperaggregability, -there was no clear effect on the frequency of attacks. Although compliance with treatAmaurosis fugax under the age of 40 years 84 ment was not confirmed this must cast doubt on the hypothesis that platelet hyperaggregability is the cause of amaurosis fugax in this age group. Unlike Preston et al's patients who seemed to respond to treatment with aspirin and persantin none of these patients had a primary haematological disorder, which may be a reason for the difference in our findings.
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